S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.35%)
BABA   86.75 (+1.41%)
AMD   102.82 (+0.06%)
T   15.03 (+0.13%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.69%)
GE   110.55 (-1.59%)
DIS   81.06 (+1.16%)
AMC   7.99 (+2.57%)
PFE   33.18 (+3.40%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:BPMC

Blueprint Medicines (BPMC) Stock Forecast, Price & News

$50.22
-0.85 (-1.66%)
(As of 09/29/2023 ET)
Compare
Today's Range
$49.91
$52.02
50-Day Range
$46.90
$66.00
52-Week Range
$37.82
$68.63
Volume
730,247 shs
Average Volume
600,163 shs
Market Capitalization
$3.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$75.21

Blueprint Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
49.8% Upside
$75.21 Price Target
Short Interest
Bearish
6.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.04mentions of Blueprint Medicines in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$847,673 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.06) to ($7.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

501st out of 973 stocks

Pharmaceutical Preparations Industry

236th out of 450 stocks


BPMC stock logo

About Blueprint Medicines (NASDAQ:BPMC) Stock

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

BPMC Price History

BPMC Stock News Headlines

Berenberg Bank Sticks to Their Buy Rating for Blueprint Medicines (BPMC)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
What 15 Analyst Ratings Have To Say About Blueprint Medicines
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Blueprint Medicines (BPMC) Gets a Buy from H.C. Wainwright
Blueprint Medicines (NASDAQ: BPMC)
See More Headlines
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Company Calendar

Last Earnings
8/02/2023
Today
9/29/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPMC
Fax
N/A
Employees
660
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$75.21
High Stock Price Forecast
$114.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+49.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-557,520,000.00
Net Margins
-245.62%
Pretax Margin
-244.46%

Debt

Sales & Book Value

Annual Sales
$204.04 million
Book Value
$8.60 per share

Miscellaneous

Free Float
58,311,000
Market Cap
$3.06 billion
Optionable
Optionable
Beta
0.74

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Ms. Kathryn Haviland (Age 47)
    Pres, CEO & Director
    Comp: $1.17M
  • Mr. Alexis A. Borisy A.M. (Age 51)
    Co-Founder & Director
    Comp: $50k
  • Mr. Michael Landsittel (Age 51)
    Chief Financial Officer
    Comp: $785.36k
  • Ms. Christina  RossiMs. Christina Rossi (Age 46)
    Chief Operating Officer
    Comp: $875.22k
  • Ms. Tracey L. McCain Esq. (Age 55)
    Exec. VP, Chief Legal & Compliance Officer and Sec.
    Comp: $764.9k
  • Dr. Fouad Namouni M.D. (Age 54)
    Pres of R&D
    Comp: $916.4k
  • Ms. Ariel Hurley (Age 49)
    Sr. VP, Fin. & Principal Accounting Officer
  • Dr. Christopher K. Murray Ph.D. (Age 59)
    Sr. VP of Technical Operations and Chief Technical Operations & Quality Officer
  • Dr. Percy H. Carter M.B.A. (Age 52)
    Ph.D., Chief Scientific Officer
  • Jenna Cohen
    Sr. Director & Head of Investor Relations













BPMC Stock - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 2 sell ratings, 3 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BPMC shares.
View BPMC analyst ratings
or view top-rated stocks.

What is Blueprint Medicines' stock price forecast for 2023?

12 equities research analysts have issued 1 year target prices for Blueprint Medicines' shares. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they expect the company's stock price to reach $75.21 in the next twelve months. This suggests a possible upside of 49.1% from the stock's current price.
View analysts price targets for BPMC
or view top-rated stocks among Wall Street analysts.

How have BPMC shares performed in 2023?

Blueprint Medicines' stock was trading at $43.81 at the beginning of the year. Since then, BPMC stock has increased by 15.2% and is now trading at $50.45.
View the best growth stocks for 2023 here
.

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our BPMC earnings forecast
.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) announced its quarterly earnings data on Wednesday, August, 2nd. The biotechnology company reported ($2.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.58) by $0.39. The biotechnology company had revenue of $57.60 million for the quarter, compared to analysts' expectations of $45.60 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 117.88% and a negative net margin of 245.62%. Blueprint Medicines's revenue for the quarter was up 57.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.68) earnings per share.

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $50.45.

How much money does Blueprint Medicines make?

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $3.06 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.22) on an earnings per share basis.

How many employees does Blueprint Medicines have?

The company employs 660 workers across the globe.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.

This page (NASDAQ:BPMC) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -